{
  "source": "PA-Med-Nec-Mavyret.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2132-10\nProgram Prior Authorization/Medical Necessity\nMedication Mavyret® (glecaprevir/pibrentasvir)\nP&T Approval Date 9/2017, 11/2018, 6/2019, 11/2019, 11/2020, 5/2021, 8/2021, 8/2022,\n7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nMavyret (glecaprevir/pibrentasvir) is a fixed-dose combination of glecaprevir, a hepatitis C\nvirus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is\nindicated for the treatment of adult and pediatric patients 3 years and older with chronic HCV\ngenotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis\n(Child-Pugh A). Mavyret is also indicated for the treatment of adult and pediatric patients 3\nyears and older with HCV genotype 1 infection, who previously have been treated with a\nregimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.1\n2. Coverage Criteriaa:\nA. For the treatment of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection in treatment-\nnaïve patients without cirrhosis or with compensated cirrhosis, Mavyret will be approved\nbased on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection\n-AND-\n2. Patient is treatment-naïve\n-AND-\n3. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n5. Physician/provider asserts patient demonstrates treatment readiness, including the ability\n© 2024 UnitedHealthcare Services Inc.\n1\nto adhere to the treatment regimen\nAuthorization will be issued for 8 weeks.\nB. For the treatment of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection in patients who are\ntreatment-experienced with",
    " adhere to the treatment regimen\nAuthorization will be issued for 8 weeks.\nB. For the treatment of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection in patients who are\ntreatment-experienced with regimens containing interferon, pegylated interferon, ribavirin,\nand/or Sovaldi (sofosbuvir) without cirrhosis, Mavyret will be approved based on all of the\nfollowing criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection\n-AND-\n2. Patient has prior treatment experience with a regimen including at least one of the\nfollowing:\na. Interferon (e.g., Intron-A)\nb. Pegylated interferon (e.g., Pegasys, PegIntron)\nc. Ribavirin (e.g., Rebetol)\nd. Sofosbuvir (e.g., Sovaldi)\n-AND-\n3. Patient has no prior treatment experience with any of the following regimens:\na. HCV NS3/4A protease inhibitor [e.g., Incivek (teleprevir), Victrelis (boceprevir),\nViekira (dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier\n(elbasvir/grazoprevir)]\nb. HCV NS5A inhibitor [e.g., Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir),\nHarvoni (ledipasvir/sofosbuvir), Viekira (dasabuvir/ombitasvir/\nparitaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. Patient is without cirrhosis\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n6. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n© 2024 UnitedHealthcare Services Inc.\n2\nAuthorization will be issued for 8 weeks.\nC. For the treatment of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection in patients who are\ntreatment-experienced with regimens containing interferon, pegylated interferon, ribavirin,\nand/or Sovaldi (sofosbuvir) with cirrhosis, Mavyret will be approved based on all of the\nfollowing criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, ",
    "terferon, pegylated interferon, ribavirin,\nand/or Sovaldi (sofosbuvir) with cirrhosis, Mavyret will be approved based on all of the\nfollowing criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection\n-AND-\n2. Patient has prior treatment experience with a regimen including at least one of the\nfollowing:\na. Interferon (e.g., Intron-A)\nb. Pegylated interferon (e.g., Pegasys, PegIntron)\nc. Ribavirin (e.g., Rebetol)\nd. Sofosbuvir (e.g., Sovaldi)\n-AND-\n3. Patient has no prior treatment experience with any of the following regimens:\na. HCV NS3/4A protease inhibitor [e.g., Incivek (teleprevir), Olysio (simeprevir),\nVictrelis (boceprevir), Viekira (dasabuvir/ombitasvir/paritaprevir/ritonavir),\nZepatier (elbasvir/grazoprevir)]\nb. HCV NS5A inhibitor [e.g., Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir),\nHarvoni (ledipasvir/sofosbuvir), Viekira\n(dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n6. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\nAuthorization will be issued for 12 weeks.\nD. For the treatment of chronic hepatitis C genotype 3 infection in patients who are treatment-\n© 2024 UnitedHealthcare Services Inc.\n3\nexperienced with regimens containing interferon, pegylated interferon, ribavirin, and/or\nSovaldi (sofosbuvir), who are without cirrhosis or have compensated cirrhosis, or is a liver\nor kidney transplant recipient, Mavyret will be approved based on all of the following\ncriteria:\n1. Diagnosis of chronic hepatitis C genotype 3 infection\n-AND-\n2. Patient has prior treatment experience with a regimen including at least one of the\nfollowin",
    "d based on all of the following\ncriteria:\n1. Diagnosis of chronic hepatitis C genotype 3 infection\n-AND-\n2. Patient has prior treatment experience with a regimen including at least one of the\nfollowing:\na. Interferon (e.g., Intron-A)\nb. Pegylated interferon (e.g., Pegasys, PegIntron)\nc. Ribavirin (e.g., Rebetol)\nd. Sofosbuvir (e.g., Sovaldi)\n-AND-\n3. Patient has no prior treatment experience with any of the following regimens:\na. HCV NS3/4A protease inhibitor [e.g., Incivek (teleprevir), Victrelis (boceprevir),\nViekira (dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier\n(elbasvir/grazoprevir)]\nb. HCV NS5A inhibitor [e.g., Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir),\nHarvoni (ledipasvir/sofosbuvir), Viekira (dasabuvir/ombitasvir/\nparitaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\nc. Patient is a liver or kidney transplant recipient\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n6. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n© 2024 UnitedHealthcare Services Inc.\n4\nAuthorization will be issued for 16 weeks.\nE. For the treatment of chronic hepatitis C genotype 1 infection in patients who are treatment-\nexperienced with an NS5A inhibitor without prior treatment with an NS3/4A protease\ninhibitor, who are without cirrhosis or have compensated cirrhosis, or is a liver or kidney\ntransplant recipient, Mavyret will be approved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient has prior treatment experience with an HCV NS5A inhibitor [e.g., Daklinza\n(daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (led",
    "sis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient has prior treatment experience with an HCV NS5A inhibitor [e.g., Daklinza\n(daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir)]. This\ndoes not include combination products also containing an NS3/4A inhibitor [e.g.,\nViekira (dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)].\n-AND-\n3. Patient has no prior treatment experience with an NS3/4A protease inhibitor [e.g.,\nIncivek (teleprevir), Olysio (simeprevir), Victrelis (boceprevir), Viekira\n(dasabuvir/ombitasvir/ paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\nc. Patient is a liver or kidney transplant recipient\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n6. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\nAuthorization will be issued for 16 weeks.\nF. For the treatment of chronic hepatitis C genotype 1 infection in patients who are treatment-\nexperienced with an NS3/4A protease inhibitor without prior treatment with an NS5A\ninhibitor, who are without cirrhosis or have compensated cirrhosis, Mavyret will be\napproved based on all of the following criteria:\n© 2024 UnitedHealthcare Services Inc.\n5\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient has prior treatment experience with an NS3/4A protease inhibitor [e.g., Incivek\n(teleprevir), Olysio (simeprevir), Victrelis (boceprevir)]. This does not include\ncombination products also containing an NS5A inhibitor [e.g., Viekira\n(dasabuvir/ombitasvir/ paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)].\n-AND-\n3. Patient has no prior treatm",
    "not include\ncombination products also containing an NS5A inhibitor [e.g., Viekira\n(dasabuvir/ombitasvir/ paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)].\n-AND-\n3. Patient has no prior treatment experience with an HCV NS5A inhibitor [e.g., Daklinza\n(daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Viekira\n(dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n6. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\nAuthorization will be issued for 12 weeks.\nG. For the treatment of hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection in kidney or liver\ntransplant recipients who are without cirrhosis or have compensated cirrhosis, Mavyret will\nbe approved based on all of the following criteria:\n1. Diagnosis of hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection\n-AND-\n2. One of the following:\n© 2024 UnitedHealthcare Services Inc.\n6\na. Patient is a liver transplant recipient\nb. Patient is a kidney transplant recipient\n-AND-\n3. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n5. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\nAuthorization will be issued for 12 weeks.\na State mandates may apply. Any federal regulator",
    " asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\nAuthorization will be issued for 12 weeks.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place\n4. References:\n1. Mavyret [package insert]. North Chicago, IL: AbbVie Inc.; October 2023.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of\nAmerica. Recommendations for Testing, Managing, and Treating Hepatitis C.\nhttps://www.hcvguidelines.org/. Accessed June 5, 2024.\n© 2024 UnitedHealthcare Services Inc.\n7\nProgram Prior Authorization/Medical Necessity – Mavyret\n(glecaprevir/pibrentasvir)\nChange Control\nDate Change\n9/2017 New program.\n11/2018 Annual review with no changes to clinical criteria. Updated references.\n6/2019 Updated indication based on label update. Added section on kidney\ntransplant patients to allow for 12 week approval based on AASLD\nguidelines.\n11/2019 Updated treatment duration for treatment naïve patients with\ncompensated cirrhosis to 8 weeks, based on updated prescribing\ninformation.\n11/2020 Annual review. Added liver transplant to clinical criteria. Updated\nreferences.\n5/2021 Removed prescriber requirement. Updated references.\n8/2021 Updated background with no changes to clinical criteria. Updated\nreferences.\n8/2022 Annual review. Revised clinical criteria for treatment-experienced liver\nor kidney transplant recipients per prescribing information. Updated\nreferences.\n7/2023 Annual review. No changes to covera",
    "022 Annual review. Revised clinical criteria for treatment-experienced liver\nor kidney transplant recipients per prescribing information. Updated\nreferences.\n7/2023 Annual review. No changes to coverage criteria. Updated references.\n7/2024 Annual review. Removed liver disease staging criteria that was included\nfor quality purposes rather than part of coverage decision. Updated\nreferences.\n© 2024 UnitedHealthcare Services Inc.\n8"
  ]
}